Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.
-
The current indications of soficitinib under development are strategically positioned within the vast dermatology market.
-
Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.
-
InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.